Gefitinib
- TRADE NAME: Iressa (AstraZeneca)
- INDICATIONS: Advanced non-small cell lung cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Tyrosine kinase inhibitor
- HALF-LIFE: 48 hours
Antifungals, BCG Vaccine, Boceprevir, Carbamazepine, Cardiac glycosides, Clozapine, Conivaptan, CYP3A4 inhibitors and inducers, Dasatinib, Deferasirox, Denosumab, Echinacea, Efavirenz, Grapefruit Juice, Itraconazole, Leflunomide, Natalizumab, Phenobarbital, Phenytoin, Pimecrolimus, Ranitidine, Rifampin, Rifapentine, Sipuleucel-T, St John's Wort, Tacrolimus, Topotecan, Trastuzumab, Vaccines, Vitamin K antagonists, Voriconazole, Warfarin
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of gefitinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/25/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
